Welcome to our dedicated page for Optinose news (Ticker: OPTN), a resource for investors and traders seeking the latest updates and insights on Optinose stock.
Optinose Inc (OPTN) is a specialty pharmaceutical innovator focused on chronic sinusitis treatments through its patented Exhalation Delivery System. This page provides investors and healthcare professionals with essential updates on regulatory developments, clinical research, and corporate milestones.
Track key developments including FDA decisions, peer-reviewed study publications, and partnership announcements. Our curated news collection helps stakeholders monitor progress in ENT-focused drug-device combinations and chronic disease management innovations.
Find verified updates on XHANCE clinical trials, financial earnings reports, and market expansion strategies. All content undergoes strict editorial review to ensure accuracy and relevance for investment research and therapeutic advancement tracking.
Bookmark this page for timely updates on Optinose's novel approaches to nasal drug delivery and specialty pharmaceutical developments. Regularly refreshed content supports informed decision-making for investors and healthcare analysts alike.
Optinose (NASDAQ:OPTN) reported preliminary net revenues of $15.4 million for XHANCE® for Q3 2020, marking a 78% increase year-over-year and a 50% increase quarter-over-quarter. This growth allows the company to consider drawing an additional $20 million under its debt facility, potentially extending its cash runway. A full financial report is expected on November 5, 2020.
Optinose announced the publication of a peer-reviewed study demonstrating the efficacy of XHANCE (EDS-FLU) in patients with nasal polyps who remain symptomatic after standard nasal steroid treatments. The study, published in the International Forum of Allergy & Rhinology, shows that patients switching to XHANCE experienced significant improvement compared to those continuing conventional treatments. As XHANCE is FDA-approved for nasal polyps in adults, this data supports its role as an important treatment option before moving to surgery or biologics. The study analyzed pooled data from NAVIGATE I and II trials.
Optinose (NASDAQ: OPTN), a pharmaceutical company specializing in ear, nose, and throat (ENT) and allergy treatments, has announced that CEO Peter Miller will present a company overview and business update at the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 2:00 p.m. ET. The presentation can be accessed via live webcast on the Optinose investors page, with a replay available for 30 days post-event. For further information, visit www.optinose.com.
Optinose (NASDAQ: OPTN) announced a public offering of 6,000,000 shares at $5.85 per share, with an additional 900,000 shares available to the underwriter. The offering is set to close on August 18, 2020, pending customary conditions. Proceeds will support working capital, the commercialization of XHANCE, and clinical development for both XHANCE in chronic sinusitis and OPN-019 for COVID-19. Credit Suisse is the sole bookrunner for the offering.
Optinose (NASDAQ: OPTN) has announced a proposed underwritten public offering of its common stock, in which all shares will be offered by the company. The underwriter will have a 30-day option to purchase an additional 15% of shares. Funds from the offering will be used for working capital, the commercialization of XHANCE, and clinical development of XHANCE for chronic sinusitis and OPN-019 for COVID-19. Credit Suisse Securities (USA) LLC is acting as the sole bookrunner. The offering is registered with the SEC under Form S-3.
Optinose (NASDAQ: OPTN) announced that it will report its second quarter 2020 financial results and corporate updates on August 4, 2020, before market open. The leadership team will host a conference call at 8:00 a.m. ET on the same day to discuss these results, including the launch of XHANCE®. Participants can join the call via U.S. or international numbers, with a replay available until August 11, 2020. The event will also be accessible through a webcast on Optinose's website.
Optinose (NASDAQ: OPTN) has appointed Catherine E. Owen to its Board of Directors. Catherine, currently Senior VP at Bristol-Myers Squibb, brings extensive global pharmaceutical experience, overseeing operations in 18 countries. Her background includes leadership roles at Johnson & Johnson, where she launched new products in immunology and infectious diseases. She began her career at AstraZeneca. Chairman Joe Scodari expressed confidence in her capabilities, emphasizing her strong marketing and strategic skills.
Optinose (NASDAQ: OPTN) has announced a co-promotion agreement with kaléo to promote XHANCE® (fluticasone propionate), an exhalation nasal spray for treating nasal polyps in adults in the U.S. The partnership aims to expand promotional reach to nearly 6,000 healthcare professionals, with kaléo leveraging its established relationships in the allergy sector. Promotional activities are expected to commence in Q4 2020. This collaboration aims to enhance awareness and usage of XHANCE in the target audience.
Optinose (NASDAQ: OPTN) has been recognized as one of the Philadelphia Business Journal’s “Best Places to Work” for 2020 in the medium-sized company category, marking the third consecutive year for this honor. The company, which employs over 200 people with a significant presence in Yardley, emphasizes a strong workplace culture and employee engagement, evidenced by an 84% participation rate in the related survey. Optinose focuses on improving the lives of patients served by ENT and allergy specialists and has made strides in launching its lead product, XHANCE.
OptiNose, Inc. (NASDAQ: OPTN) has announced that its 2020 Annual Meeting of Stockholders will now take place virtually on June 10, 2020, at 8:30 AM ET, due to COVID-19 safety concerns. Online access will start at 8:15 AM ET. Stockholders cannot attend in person but will have equivalent participation rights as in a physical meeting. Voting is encouraged before the meeting, and those who haven't yet voted can do so electronically during the meeting. Details are available on the Optinose website.
